Clinical Trial Issues
Most clinical trials with testosterone replacement treatment have been done in postpubertal males with hypogonadism from various causes. With few exceptions, they have been open-label double-blind studies would be a challenge, although preferable. Total testosterone concentrations have generally been used for the diagnosis of androgen deficiency and for adequacy of replacement testosterone therapy. Free or bioavailable testosterone concentrations may provide a better basis for diagnosis of...
The Diagnosis of Benign Prostatic Hyperplasia
Several guidelines have been published to aid in the diagnosis of BPH the most prominent ones are those published by the American Urological Association (AUA)9 and by the European Association of Urology (EAU).29 Both of these guidelines recommend that the diagnosis of BPH is based on a medical history, symptomatic assessment using a validated instrument such as the International Prostate Symptom Score (IPSS), which uses eight items to categorize BPH 'urinary' symptoms as mild (IPSS 0-7),...
Age Related Macular Degeneration
6.12.5.2.1 Dry age-related macular degeneration Perhaps the most significant hurdle for dry AMD clinical trials is that disease onset occurs late in life as a cumulative result of chronic damage to the RPE cells and their dependent photoreceptors. Most dry AMD patients are likely unaware of their disease until visual acuity begins to decline, at which point substantial morphological damage and dysfunction have occurred. It is thus unclear that intervening in a recognized AMD risk-increasing...
- A71623
- Abcg1 - 2
- Acknowledgments
- Acute and Neuropathic Pain
- AcylCoAcholesterol acyltransferase inhibitors
- Addictionsubstance abuse
- Adenosine A2A receptor antagonists
- Adenosine Producing Stem Cell Therapy
- Advantages - 2
- Ag13958
- Age Related Macular Degeneration 612621 Dry agerelated macular degeneration
- Al34662
- Alcohol Addiction
- Alteplase
- AMPA antagonists
- Aneurysmal Subarachnoid Hemorrhage
- Angiotensin II Ang II Antagonists or Blockers
- Angiotensin Converting Enzyme Inhibitors
- Animal Models and Preclinical Studies
- Animal Models of Anesthetic Action
- Antiarrhythmic Drugs Combining Actions of Classes
- Antiarrhythmics
- Anticholinergic Agents
- Antiepileptic Drug Mechanisms
- Arrhythmias
- Assessing Disease Activity
- Atorvastatin
- Atrial Arrhythmias
- Attention Deficit Hyperactivity Disorder
- Attention deficithyperactivity disorder
- Auda
- Autoimmuneneuromuscular disorders
- B and T Cell depletion mechanisms
- Background
- Bdnf
- Behavioral Environmental Modification
- Biguanides
- Biographies
- Biomarkers for Neuroprotective Drug Evaluation
- Biomarkers in depression and bipolar disorder The main uses of biomarkers in drug development are11
- Bladder Dysfunction
- Bone Cells
- Bone Remodeling
- Bone Structure
- Bphc
- Bridging studies
- Broader Efficacy
- C02c2h5 C02g2h5
- C2h5
- Calcium Channel Blockers
- CAMP response elementbinding protein CREB
- Cardiac Ion Channels
- Catechol Omethyltransferase
- Catechol Omethyltransferase inhibitors
- Cee03310
- Central Nervous System Disorders Psychiatric and Neurodegenerative
- Cerivastatin
- Cgrp
- Ch - 2
- Ch3 - 2 3 4 5
- Cholesteryl ester transfer protein inhibitors
- Choosing behavioral assays
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Chronic Models in Higher Species
- Classification Systems for Antiarrhythmic Drugs
- Clinical Efficacy
- Clinical Study Requirements
- Clinical Trial Issues - 2 3 4 5 6 7 8 9 10 11 12 13 14 15
- Clinical use - 2 3 4
- Cn
- Combination Therapy
- Comparisons of rosiglitazone and pioglitazone
- Conclusion
- Conclusions
- Conditioned avoidance
- Conflict Models
- Corticosteroids
- Costimulatory molecule inhibitors
- Cpmp
- Current and Targeted Medications
- Current Thrombolytics
- Current Treatment - 2 3 4 5 6 7 8
- Current Treatments - 2
- D
- Defensive Burying
- Dexanabinol HU211
- Dht
- Diabetes Syndrome X
- Diagnosis - 2
- Disadvantages - 2 3
- Disease Basis - 2 3
- Disease Basis Genetic and Environmental Triggers 4 5 6 7
- Disease Models
- Disease State - 2
- Disease State Diagnosis - 2 3
- Disease Specific Animal Models
- Disruptedin Schizophrenia 1 DISC1
- Diuretics
- Dopamine metabolism inhibitors
- Dopamine receptor agonists
- Dopamine Receptor Modulators Dopamine Partial Agonists
- Dopamine replacement
- Dopamine transporter polymorphisms
- Drug Classification
- Drugs that Block Other Ion Channels Pumps or Transporters
- E4031
- Endothelin Receptor Antagonists
- Epidemiological Status
- Epoxyeicosatrienoic Acid Mimetics and Soluble Epoxide Hydrolase Inhibitors
- Eradication of Helicobacter pylori
- Evidence Based Approaches
- Experimental Disease Models - 2 3 4 5 6 7 8 9 10 11
- Experimental Pain Models
- F - 2
- Awm
- Ddi
- Fhs
- Fmk
- Ggx
- Mwm
- Ost
- F3c
- Factors Affecting Thrombus Formation
- Figure 7 The structures of 5fluoruracil and mitomycin C
- First Generation Typical Antipsychotic Drugs
- Fluvastatin
- Free Radical Scavengers Antioxidants
- Fsh
- Ft ft
- Future Aspects
- Future Directions - 2 3 4
- Future Prospects - 2
- GABAergic
- Gene Therapy
- General Considerations for Modeling Attention Defect Hyperactivity Disorder 605411 Diverse clinical symptoms with unknown etiology
- Genetic Insights
- Genetic Models
- Genetic models
- Genetic Models of Epilepsy - 2
- Genetic risk factors
- Genetics
- Genetics of Epilepsy
- Glaucoma
- Glitinides nonsulfonylurea secretagogues
- Global depression market
- Glucocorticoids
- Glutamate Antagonists
- Glutamate Modulators
- Glycoprotein IIbIIIa Receptor Antagonists
- Group I mGlu antagonists
- Group II mGlu agonists
- Guillain Barre syndrome
- Guillain Barre Syndrome
- H - 2
- Ci
- Dhh
- Dni
- Ybd
- Yrx
- H2 Receptor Antagonists
- H3c - 2 3 4 5
- Hemorrhagic Stroke Models
- Hh
- High Density Lipoprotein Cholesterol Elevating Agents - 2 3
- Highdensity lipoprotein structure and composition
- Histamine receptor antagonists
- Historical Overview
- Historical Perspective
- Historically used Agents
- Hn - 2
- Ho - 2
- Ho V
- Hormone Replacement
- HT1A Agonists
- Human Genetics
- Hyperplasia Prostate Dysfunction
- I - 2
- Traf6
- Iii
- Ileal bile acid transporter IBAT and apical sodiumcodependent bile acid transporter ASBT inhibitors
- Im Ai
- Im Im Im
- In Vitro Models
- In Vivo Models
- Info - 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66
- Inhibition of Apoptotic Neurodegeneration
- Inhibition of Calpain Mediated Proteolytic Damage
- Inhibitors of the Synthesis of 20Hydroxyeicosatetraenoic Acid
- Intravenous Immunoglobulin and Plasma Exchange
- Introduction - 2 3 4 5 6 7 8 9 10 11
- Irritable Bowel Syndrome
- Jo
- Jtt705
- K1
- Kc11458
- Laam
- Lanoteplase nPA
- Latent inhibition
- Lesion Models
- Lessons Learnt from Past Clinical Trials of Neuroprotective Agents
- Light Dark
- Lipoproteina and Coronary Heart Disease Risk
- Lipoproteins Composition Structure Function and Lipid Transport
- Locomotor activity
- Low Density Lipoprotein Cholesterol Lowering Agents
- Lowdensity lipoprotein oxidation modification and retention
- Lowdensity lipoprotein structure and composition
- Lower Urinary Tract Symptoms and Sexual Dysfunction
- M
- M2
- Management Approaches
- Mcab
- Mechanism of Thrombolysis
- Mechanisms of action - 2 3
- Medical Management with Thrombolysis
- Melanocortins
- Mevastatin and lovastatin
- Miscellaneous associations
- Mixedlineage kinase inhibitors
- Mk677
- Models of Emesis
- Modulating the Renin Angiotensin System
- Monoamine Transport Inhibitors
- Murine Models of Atherosclerosis
- Muscarinic acetylcholine receptors mAChRs
- Muscarinic Agonists
- Myasthenia Gravis
- N - 2 3 4 5 6 7 8 9
- N Pullen and J D Gale Pfizer Global Research and Development Sandwich UK 2007 Elsevier Ltd All Rights Reserved 10 11 12 13 14
- NAcetyl LaspartylLglutamate
- Natural models
- Nda
- NDesmethyclozapine
- Neuregulin
- Neurocircuitry
- Neurodegeneration
- Neurodegenerative Diseases
- Neuroimaging
- Neuroimmunophilins
- Neurokinin3 Antagonists
- Neuromuscular Autoimmune Disorders
- Neuronal Nicotinic Receptor Agonists
- Neuropeptide approaches
- Neuroprotectants
- Neurorestorative Drug Discovery
- Neurotrophic Neuroprotectant small molecules
- New Analgesic Targets
- New Antiarrhythmics Classes
- New Concept Concerning Glutamate Mediated Excitotoxicity
- New Research Areas - 2 3 4 5 6 7 8 9 10 11
- Newer Anticonvulsant Drugs
- Ngf
- Nh
- Niacin as a highdensity lipoprotein cholesterolelevating agent
- Nicotinic acetylcholine receptors nAChRs
- NMethyl Daspartate NMDA receptor antagonists
- No2
- Noradrenergic
- Novel GABA Transporter GAT Inhibitors
- Nr
- Nxyc59
- O - 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
- O2no
- Obesity
- Obesity Disorders of Energy
- Obsessive compulsive disorder
- Ocular Surface Diseases
- Oh - 2 3
- Open Field
- Ophthalmic agents
- Oral 5lipoxygenaseactivating protein inhibitors
- Osteoblasts
- Osteoclasts
- Osteocytes
- Other Considerations
- Other local factors regulating bone resorption
- Other Prostatitic Conditions Causing Incontinence
- Other Therapies for Arrhythmias
- Overview
- Overview and Comparison of Drug Classes
- Overview of Current Electrical Treatments for Arrhythmias
- Overview of Secondary Central Nervous System Injury
- P2Y12 Antagonists
- PAdrenoceptor Blockers
- Pain Overview
- PAmyloid aggregation blockers
- Pathophysiology of Thrombus Formation
- Patient Selection
- Pdt
- Peripheral Artery Disease
- Peroxisome proliferatoractivated receptor agonists
- Pharmacokinetics - 2 3 4
- Pharmacological and lesion models
- Pitavastatin
- Posttraumatic Stress Disorder
- Ppp
- Pravastatin
- Preclinical Study Requirements
- Prepulse inhibition
- Prescription trends
- Prevalence
- Primary endpoint
- Proinflammatory Cytokines and Their Receptors
- Prolyl endopeptidase inhibitors
- Proton Pump Inhibitors
- Q - 2
- Qt
- QTc liability
- Quality of Life
- R - 2 3
- Ra Fatty Acids
- Rating scales
- Reduced Side Effect Liability
- ReEstablishing Mucosal Tolerance Probiotics Prebiotics Worms and Toll Like Receptor Modulators
- References - 2 3 4 5 6
- Regulation of osteoblasts
- Regulation of osteoclasts
- Renal Dysfunction
- Renin Inhibitors
- Reteplase
- Rima
- Risk Factors
- Rosuvastatin
- Rp67580
- Rrms
- Rsd 1070
- S
- Saruplase
- Sb656104a
- Schizophrenia
- Second Generation Atypical Antipsychotic Drugs
- Secretase inhibitors
- Seizure Classification
- Selective Adhesion Molecule Inhibitors
- Serotonergic
- Serotonin transporter polymorphisms
- Sex hormones
- Sexual Dysfunction
- Side effectscontraindications - 2 3
- Simvastatin
- Social anxiety disorder
- Social Cost and Market
- Social Interaction SI Test
- Special Issues
- Spinal Cord Injury Models
- Sr141716a
- Sri
- Stimulant Addiction
- Streptokinase
- Stress Induced Hyperthermia
- Stroke Traumatic Brain and Spinal Cord Injuries
- Subdural Hematoma Model
- Subtype Selective GABAa Receptor Modulators
- Summary - 2 3
- Superoxide dismutase mimetics
- Symptomatic Epilepsy
- Systemic Lupus Erythematosus
- T
- Table 2 Reasons for past failures in stroke and TBI drug discovery and development
- Table 2 Types of seizure
- Tau kinase inhibitors
- Tenecteplase TNKtPA
- The amyloid hypothesis
- The atheroprotective effects of highdensity lipoprotein cholesterol
- The cholinergic hypothesis
- The Clozapine Hypothesis
- The CRF hypothesis and stress
- The Definition of Benign Prostatic Hyperplasia
- The Dopamine DA Hypothesis
- The Future
- The inflammatory cascade hypothesis
- The monoamine theory
- The Ninds Anticonvulsant Screening Program
- The Role of Modified Low Density Lipoprotein Inflammatory Mediators and Reactive Oxygen Species ROS in Atherosclerosis
- The Serotonin 5HT Hypothesis
- The tau hypothesis
- The yAmino Butyric Acid GABA Hypothesis
- Thiazolidinediones
- Thyrotropinreleasing hormone agonists
- Thyrotropin Releasing Hormone Analogs
- Torcetrapib
- Trace Amines
- Transgenic and knockdown and out mice models of psychiatric disease
- Traumatic Brain Injury Models
- Treatment Challenges
- Treatment Complications and Progression
- Types of Arrhythmias Characteristics Prevalence Demographics and Symptoms
- Types of depression
- Unmet Clinical Needs
- Unmet Medical Need - 2 3 4
- Unmet Medical Needs - 2 3 4 5 6 7 8
- Use of Biomarkers
- V
- Vasopeptidase Inhibitors
- Ventricular Arrhythmias
- Very lowdensity lipoprotein chylomicrons and triglyceride transport
- Vesicular neurotransmitter transporters VMATs and neurotransmitter transporters SCDNTs
- Vip No
- Warfarin Heparin and Low MolecularWeight Heparins
- X
- YAminobutyric acid receptor antagonists
- Yh 1885